CEO Michelle Berrey said Chimerix Inc.'s solid financial position of $378 million in cash at the end of the third quarter will let the firm "make the best strategic decisions around the brincidofovir programs" after the oral nucleotide analog's top-line phase III failure in the trial called SUPPRESS, which tested the compound against cytomegalovirus in hematopoietic cell transplant patients.